Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance

AI-generated analysis

πŸ“Š Bristol Myers Squibb (BMY) holds a diversified portfolio across oncology, immunology, cardiovascular, and neuroscience with key therapies like Opdivo and Reblozyl driving growth.

πŸ”¬ The company's core growth franchise accounted for approximately 55% of total revenues in 2025, supported by strong momentum from immuno-oncology products.

πŸ’‰ New launches such as the subcutaneous Opdivo Qvantig and melanoma standard-of-care Opdualag are expanding the immunotherapy platform with early adoption in the US.

πŸš€ Partnerships like the co-development deal with BioNTech for pumitamig aim to advance bispecific antibody therapies targeting solid tumors with promising phase II data.

πŸ“‰ Legacy products representing 45% of revenues face generic competition, prompting BMY's acquisition of Orbital Therapeutics to bolster its RNA CAR-T candidate pipeline.

⚠️ Financial risk is elevated due to aggressive deal-making, resulting in a debt-to-capital ratio of 70.9% as of Dec. 31, 2025, alongside $42.8 billion in long-term debt.

πŸ“ˆ Gilead Sciences (GILD) maintains dominant market leadership in HIV treatment with Biktarvy holding over 52% market share and Descovy capturing 45% of the PrEP US market.

πŸ’Š Prevention portfolio sales surged 47% in 2025, offsetting a $900 million headwind from Medicare Part D redesign to deliver an overall HIV franchise growth of approximately 6%.

🦠 The FDA approval of injectable lenacapavir (Yeztugo) strengthens Gilead's HIV portfolio with twice-yearly dosing and projected revenues near $800 million in 2026.

🩺 Gilead advanced its liver disease franchise with the approval of seladelpar (Livdelzi), which became the market leader in second-line primary biliary cholangitis treatments in the US.

πŸ’Š Oncology diversification includes the Cell Therapy franchise and breast cancer drug Trodelvy, which has performed well since initial approval.

🌐 Both companies boast strong global presence and shareholder return track records, making valuation, fundamentals, and risk profiles critical for investor decision-making.

πŸ“‰ Gilead is prioritizing long-acting integrase inhibitor programs to further solidify its HIV dominance and manage future growth drivers.

Bullish Signals
  • Bristol Myers Squibb's immuno-oncology franchise continues strong momentum with new products like Camzyos, Breyanzi, and Reblozyl driving growth.
  • Opdivo remains the top revenue generator, aided by ongoing label expansions and sustained market share gains in first-line non-small cell lung cancer.
  • The rollout of Opdivo Qvantig is strengthening the immuno-oncology platform with encouraging early adoption in the United States.
  • Opdualag has emerged as a standard-of-care option in first-line melanoma and is delivering solid growth.
  • Reblozyl exceeded $2 billion in annualized sales, driven by robust uptake in first- and second-line MDS-related anemia.
  • Breyanzi has surpassed a $1 billion run rate with further upside expected in 2026 due to strong demand and additional label expansions.
  • Cobenfy posted a promising launch generating $155 million in 2025 as access broadens across care settings.
  • The acquisition of Orbital Therapeutics adds OTX-201, a preclinical RNA CAR-T candidate targeting autoimmune diseases, strengthening the pipeline.
  • Partnership with BioNTech to co-develop pumitamig (BNT327) showed encouraging efficacy and manageable safety in early phase II data for triple-negative breast cancer.
  • Gilead's HIV product sales grew 10% excluding a $900 million Medicare Part D redesign headwind, with Biktarvy holding more than 52% market share.
  • Descovy sales increased 31% year over year to $2.8 billion and accounts for more than 45% of the U.S. market share in pre-exposure prophylaxis (PrEP).
  • FDA approval of injectable lenacapavir, Yeztugo, positions it as a key incremental growth driver with projected revenues of approximately $800 million in 2026.
  • Gilead expects total HIV sales to grow approximately 6% year over year, strengthening its dominant franchise.
  • The FDA approval of seladelpar (Livdelzi) for primary biliary cholangitis has strengthened Gilead's liver disease portfolio, making it the market leader in second-line PBC in the United States.
  • Gilead's oncology portfolio is diversified with Trodelvy performing well since its approval in the breast cancer drug market.
Risk Factors
  • Bristol Myers Squibb's aggressive deal-making strategy has significantly increased leverage, with a debt-to-capital ratio of 70.9% as of Dec. 31, 2025, highlighting a key financial risk alongside its growth ambitions.
  • Legacy products account for approximately 45% of Bristol Myers Squibb's revenues and face mounting generic competition, which is expected to weigh on near-term top-line growth.
  • Bristol Myers Squibb's HIV product growth faced an estimated $900 million headwind from the Medicare Part D redesign in 2025, dampening otherwise strong performance.
  • Gilead Sciences' HIV sales growth was impacted by regulatory headwinds and market share pressures on key products like Biktarvy despite maintaining dominant positions.
Full Analysis
Bristol Myers Squibb (BMY) and Gilead Sciences (GILD) represent two distinct approaches within the biotechnology sector, offering investors a choice between diversified oncology portfolios and dominant franchise-driven models. Bristol Myers Squibb derives approximately 55% of its revenue from its growth portfolio anchored by immuno-oncology therapies, with Opdivo remaining the primary revenue driver following label expansions in non-small cell lung cancer. Newer products such as Camzyos, Breyanzi, and Reblozyl are fueling momentum, while legacy products accounting for the remaining 45% face increasing generic competition. To counter this pressure, Bristol Myers has increased its debt-to-capital ratio to 70.9% by December 31, 2025, holding $10.2 billion in cash against $42.8 billion in long-term debt, as it pursues strategic acquisitions like Orbital Therapeutics and partnerships with BioNTech. In contrast, Gilead Sciences maintains a market-leading position in HIV treatment and prevention, with its flagship therapies Biktarvy and Descovy driving growth despite a headwind from Medicare Part D redesign. While total HIV sales grew 6% in 2025 excluding the headwind to reach estimated projections, key products like Biktarvy hold over 52% market share and Descovy saw a 31% increase in sales to $2.8 billion. Gilead is also expanding its liver disease portfolio with the approval of seladelpar (Livdelzi) for primary biliary cholangitis and advancing long-acting integrase inhibitor programs, such as injectable lenacapavir under the brand name Yeztugo, which management projects will generate approximately $800 million in revenue in 2026. Both companies possess strong global presence and a history of delivering shareholder returns, yet they face different risk profiles regarding financial leverage and portfolio composition. Bristol Myers Squibb's aggressive acquisition strategy increases financial risk but aims to strengthen its oncology pipeline with assets like OTX-201 for autoimmune diseases. Gilead Sciences leverages its dominant HIV franchise which is supported by new approvals in long-acting treatments, while also diversifying into liver disease and oncology through its Cell Therapy franchise and the breast cancer drug Trodelvy. Ultimately, investors must weigh Bristol Myers Squibb's higher debt levels against its diversified growth opportunities against Gilead Sciences' stable cash flow generation from its HIV dominance and emerging pipeline advancements in liver disease and oncology.